Mathias Locher

1.4k total citations
31 papers, 1.1k citations indexed

About

Mathias Locher is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mathias Locher has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Molecular Biology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mathias Locher's work include Monoclonal and Polyclonal Antibodies Research (9 papers), CAR-T cell therapy research (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Mathias Locher is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), CAR-T cell therapy research (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Mathias Locher collaborates with scholars based in Germany, United States and Switzerland. Mathias Locher's co-authors include Patrick A. Baeuerle, Peter Kufer, Bernd Schlereth, Klaus Brischwein, Róbert Hermann, Andreas Wolf, Nadja Prang, Robert Hofmeister, Norbert Knebel and Peter A. Kiener and has published in prestigious journals such as Biochemical Pharmacology, European Journal of Cancer and Metabolism.

In The Last Decade

Mathias Locher

31 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mathias Locher Germany 18 478 417 376 359 84 31 1.1k
Susan Chung United States 16 391 0.8× 90 0.2× 1.4k 3.8× 227 0.6× 16 0.2× 21 2.0k
Victor Umansky Germany 18 401 0.8× 45 0.1× 408 1.1× 674 1.9× 125 1.5× 40 1.3k
Roland Greimers Belgium 18 227 0.5× 46 0.1× 597 1.6× 417 1.2× 36 0.4× 67 1.4k
Angelika Grossmann United States 20 124 0.3× 159 0.4× 439 1.2× 661 1.8× 65 0.8× 33 1.6k
K Tanaka Japan 20 546 1.1× 38 0.1× 1.7k 4.5× 266 0.7× 99 1.2× 32 2.1k
Corinne Henriquet France 18 120 0.3× 55 0.1× 608 1.6× 130 0.4× 73 0.9× 27 1.3k
István Kurucz Hungary 17 76 0.2× 181 0.4× 561 1.5× 212 0.6× 14 0.2× 42 960
Jens Holmberg Sweden 13 240 0.5× 114 0.3× 388 1.0× 769 2.1× 14 0.2× 16 1.3k
Jyotsnabaran Halder United States 14 321 0.7× 37 0.1× 654 1.7× 182 0.5× 10 0.1× 15 1.4k
Brigitte Lacroix France 15 149 0.3× 72 0.2× 309 0.8× 47 0.1× 33 0.4× 24 930

Countries citing papers authored by Mathias Locher

Since Specialization
Citations

This map shows the geographic impact of Mathias Locher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathias Locher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathias Locher more than expected).

Fields of papers citing papers by Mathias Locher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathias Locher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathias Locher. The network helps show where Mathias Locher may publish in the future.

Co-authorship network of co-authors of Mathias Locher

This figure shows the co-authorship network connecting the top 25 collaborators of Mathias Locher. A scholar is included among the top collaborators of Mathias Locher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathias Locher. Mathias Locher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brennan, Frank R., Andreas Baumann, Lolke de Haan, et al.. (2015). Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies. Regulatory Toxicology and Pharmacology. 73(1). 265–275. 13 indexed citations
2.
Silacci, Michela, Richard Woods, Sarah Batey, et al.. (2015). Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. mAbs. 8(1). 141–149. 77 indexed citations
3.
Baumann, Andreas, Kelly M. Flagella, Roy Forster, et al.. (2014). New challenges and opportunities in nonclinical safety testing of biologics. Regulatory Toxicology and Pharmacology. 69(2). 226–233. 19 indexed citations
4.
Brandl, Christian, Nadja Prang, Ralf Lutterbuese, et al.. (2008). Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leukemia Research. 33(3). 465–473. 58 indexed citations
5.
6.
Lutterbuese, Petra, Klaus Brischwein, Robert Hofmeister, et al.. (2006). Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunology Immunotherapy. 56(4). 459–468. 10 indexed citations
7.
Brischwein, Klaus, Bernd Schlereth, Andreas Wolf, et al.. (2005). MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Molecular Immunology. 43(8). 1129–1143. 212 indexed citations
8.
Hermann, Róbert, et al.. (2004). Intranasal Loteprednol Etabonate in Healthy Male Subjects: Pharmacokinetics and Effects on Endogenous Cortisol. The Journal of Clinical Pharmacology. 44(5). 510–519. 7 indexed citations
9.
Walgren, Jennie, et al.. (2004). Effect of R(+)α-Lipoic acid on pyruvate metabolism and fatty acid oxidation in rat hepatocytes. Metabolism. 53(2). 165–173. 29 indexed citations
10.
Nagaraja, N., Katharina Erb, Christine Klipping, et al.. (2003). Pharmacokinetic/Pharmacodynamic Modeling of Luteinizing Hormone (LH) Suppression and LH Surge Delay by Cetrorelix after Single and Multiple Doses in Healthy Premenopausal Women. The Journal of Clinical Pharmacology. 43(3). 243–251. 18 indexed citations
11.
Hermann, Róbert, et al.. (2003). Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. European Journal of Clinical Pharmacology. 58(12). 795–802. 46 indexed citations
12.
Nagaraja, N., et al.. (2000). Pharmacokinetic‐Pharmacodynamic Modeling of Testosterone and Luteinizing Hormone Suppression by Cetrorelix in Healthy Volunteers. The Journal of Clinical Pharmacology. 40(3). 266–274. 27 indexed citations
13.
Knebel, Norbert, et al.. (2000). Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 748(1). 97–111. 26 indexed citations
14.
Knebel, Norbert, et al.. (1999). Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 721(2). 257–269. 17 indexed citations
15.
Niebch, G, et al.. (1997). Enantioselective high-performance liquid chromatography assay of (+)R- and (?)S-?-lipoic acid in human plasma. Chirality. 9(1). 32–36. 31 indexed citations
16.
Blaschke, Gottfried, et al.. (1997). Investigation of the stereoselective in vitro metabolism of the chiral antiasthmatic/antiallergic drug flezelastine by high-performance liquid chromatography and capillary zone electrophoresis. Journal of Chromatography B Biomedical Sciences and Applications. 691(2). 463–471. 15 indexed citations
17.
Borbe, Harald O., et al.. (1996). In vivo incorporation of lipoic acid enantiomers and homologues in the pyruvate dehydrogenase complex from Escherichia coli. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1297(1). 90–98. 3 indexed citations
18.
Locher, Mathias, et al.. (1995). Interaction of α-Lipoic acid enantiomers and homologues with the enzyme components of the mammalian pyruvate dehydrogenase complex. Biochemical Pharmacology. 50(5). 637–646. 29 indexed citations
19.
Locher, Mathias, et al.. (1994). High-performance liquid chromatographic assay for the determination of the decapeptide cetrorelix, a novel luteinizing hormone-releasing hormone antagonist, in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 653(1). 102–105. 10 indexed citations
20.
Niebch, G, et al.. (1991). Metabolic fate of the novel antihypertensive drug naftopidil.. PubMed. 41(10). 1027–32. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan Chung Breakdown of academic impact, for papers by Victor Umansky Breakdown of academic impact, for papers by Roland Greimers Breakdown of academic impact, for papers by Angelika Grossmann Breakdown of academic impact, for papers by K Tanaka Breakdown of academic impact, for papers by Corinne Henriquet Breakdown of academic impact, for papers by István Kurucz Breakdown of academic impact, for papers by Jens Holmberg Breakdown of academic impact, for papers by Jyotsnabaran Halder Breakdown of academic impact, for papers by Brigitte Lacroix
Rankless by CCL
2026